<DOC>
	<DOC>NCT01181622</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of denufosol 60 mg TID in pediatric CF patients 2 to 4 years of age</brief_summary>
	<brief_title>A Safety and Tolerability Study of Denufosol in 2-4 Year Olds</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Have a confirmed diagnosis of CF Have oxyhemoglobin saturation â‰¥ 95% prior to randomization Have acute intercurrent respiratory infection (cough, wheezing, or new rhinorrhea or nasal congestion) Have any significant medical condition not related to CF Unable to discontinue use of hypertonic saline</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>